Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Acute Kidney Injury Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The global market for acute kidney injury (AKI) has experienced substantial expansion, with projections indicating continued robust growth; it is anticipated to rise from $5.72 billion in 2025 to $6.09 billion in 2026, reflecting a compound annual growth rate of 6.5%. This upward trajectory in the historical period can be attributed to several key factors, including restricted access to sophisticated kidney care solutions, the increasing incidence of coexisting health conditions such as diabetes and high blood pressure, enhancements in healthcare facility infrastructure, the widespread use of established dialysis methods, and a heightened understanding of the complications associated with AKI.
The market for acute kidney injury is poised for considerable expansion over the coming years, projected to reach $7.78 billion by 2030, reflecting a compound annual growth rate of 6.3%. This anticipated growth trajectory is fueled by several key factors, including advancements in renal replacement therapies, the emergence of new nephroprotective medications, an increase in ambulatory surgical centers, greater utilization of biomarkers for prompt identification of the condition, and the incorporation of AI-driven monitoring systems into kidney care practices. Dominant trends expected to shape this market during the forecast period encompass a rising uptake of dialysis and pharmaceutical treatments, an escalating global prevalence of acute kidney injury, heightened emphasis on early detection and biomarker research, broader applications for urinary implants, and the integration of minimally invasive approaches in managing acute kidney injury.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21079&type=smp
#Acute Kidney Injury Market Demand Drivers Creating New Revenue Opportunities
The escalating incidence of diabetes is poised to significantly boost the expansion of the acute kidney injury market. Diabetes, a cluster of conditions defined by elevated blood glucose, arises from either insufficient insulin production or cellular unresponsiveness to insulin. This growing diabetes epidemic is fueled by factors including surging obesity rates, suboptimal dietary habits, inactive lifestyles, an aging global population, and improved detection methods. Acute kidney injury introduces metabolic and inflammatory shifts that can affect how the body handles insulin and maintains glucose balance, revealing a complicated relationship that might influence the advancement and control of diabetes. Illustrating this connection, the UK’s Office for Health Improvement & Disparities reported in March 2024 that from March 2022 to March 2023, the proportion of patients with type 1 diabetes receiving all eight essential care procedures saw a 22% uplift, while type 2 diabetes registered a 21% increase, and the metric for achieving targeted HbA1c levels climbed to 37.9%, marking a record high in the National Diabetes Audit. Consequently, the rising prevalence of diabetes serves as a key driver for the growth observed in the acute kidney injury market.
Acute Kidney Injury Market Categorization By Product Type And Application
The acute kidney injury market covered in this report is segmented –
1) By Injury: Pre-Renal Kidney Injury, Post-Renal Kidney Injury, Intrinsic Kidney Injury
2) By Treatment Type: Renal Replacement Therapy (RRT), Pharmacological Management, Supportive and Conservative Management, Obstruction-Relief Interventions
3) By End User: Hospitals, Dialysis Centers, Specialty Clinics, Other End Users
Subsegments:
1) By Pre-Renal Kidney Injury: Hypovolemia, Heart Failure-Related Injury, Sepsis-Induced Injury, Renal Artery Stenosis, Hepatorenal Syndrome
2) By Post-Renal Kidney Injury: Ureteral Obstruction, Bladder Outlet Obstruction, Prostate Enlargement (Benign Prostatic Hyperplasia), Kidney Stones, Tumors Affecting Urinary Tract
3) By Intrinsic Kidney Injury: Acute Tubular Necrosis (ATN), Acute Interstitial Nephritis (AIN), Glomerulonephritis, Vasculitis, Rhabdomyolysis-Induced Injury
Acute Kidney Injury Market Trends Driving Strategic Industry Expansion
Entities prominent within the acute kidney injury (AKI) market are prioritizing the acquisition of regulatory endorsements, a strategic move aimed at broadening their existing offerings and introducing innovative therapeutic avenues. Such regulatory endorsements signify the formal sanction from governing authorities, like the FDA or EMA, permitting a product’s introduction to the market subsequent to its demonstration of meeting stringent criteria for safety, effectiveness, and quality. As an illustration, in December of 2023, Mission Therapeutics Ltd., a biotechnology firm situated in the United Kingdom, secured FDA clearance to commence a Phase II clinical investigation for its primary compound, MTX652, intended for the treatment of acute kidney injury (AKI) in individuals categorized as high-risk following cardiac procedures. This therapeutic agent is engineered to interact with vital pathways implicated in kidney damage and subsequent healing, with the objective of mitigating inflammation, averting additional renal deterioration, and fostering recuperation. A distinctive aspect of this particular trial lies in its emphasis on employing groundbreaking therapeutic approaches to tackle the foundational molecular origins of AKI, potentially yielding more impactful treatment strategies than current modalities. The forthcoming Phase II evaluation will meticulously assess MTX652’s safety profile, its therapeutic effectiveness, and its pharmacokinetic properties, thereby furnishing essential data that could underpin wider clinical acceptance and eventual market approval.
Acute Kidney Injury Market Company Landscape And Strategic Competition
Major companies operating in the acute kidney injury market are Fresenius Medical Care AG & Co. KGaA, Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Asahi Kasei Medical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB
Access The Complete Acute Kidney Injury Market Report:
https://www.thebusinessresearchcompany.com/report/acute-kidney-injury-global-market-report
#Acute Kidney Injury Market Largest Region: Which Geography Holds The Highest Market Share?
North Americawas the largest region in the acute kidney injury market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the acute kidney injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
